Centocor’s ustekinumab will face FDA committee
Executive Summary
The Dermatologic and Ophthalmic Drugs Advisory Committee will meet June 17 to discuss Centocor's BLA for ustekinumab. The human monoclonal antibody, which targets interleukin-12 and IL-23, is proposed for the treatment of moderate to severe psoriasis. The Johnson & Johnson subsidiary filed the BLA in December, putting it in position to be first-in-class for the condition